Jenoptik (JEN) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
25 Mar, 2026Executive summary
Implemented a new organizational structure, enhancing accountability, transparency, and customer focus.
Brought new micro-optics fab in Dresden online, supporting future growth and semiconductor inspection capabilities.
Profitable growth expected for 2026 after a challenging 2025 marked by weak demand in semiconductor equipment and automotive sectors.
Substantial progress on strategic goals, especially in semi inspection and efficiency programs; intensified cost management.
Free cash flow significantly improved despite revenue and EBITDA declines.
Financial highlights
Revenue declined by 6.3% year-over-year to €1,046.0m, impacted by weaker order intake and FX headwinds.
EBITDA reached €192.5m, down 13.1% year-over-year; margin contracted by 150 bps.
Earnings per share at €1.26, down from €1.62 in 2024.
Free cash flow rose 48% to €152.4m, supporting debt reduction.
Dividend proposed at €0.40, up from €0.38.
Outlook and guidance
Revenue expected to increase in the single-digit percentage range in 2026.
EBITDA margin guidance for 2026 set at 19%-21%.
CapEx/investments projected slightly below 2025, trending toward maintenance levels.
Q1 2026 revenue anticipated below Q1 2025 due to order book structure.
Guidance assumes stable political and economic conditions; improved demand expected in semi and defense businesses.
Latest events from Jenoptik
- 2025 saw lower revenue but improved cash flow, with growth expected to resume in 2026.JEN
Investor presentation25 Mar 2026 - Revenue and earnings up, 2024 guidance confirmed amid robust semiconductor demand.JEN
Q2 20241 Feb 2026 - Revenue and EBITDA rose, but 2025 targets postponed to 2026 amid industry delays.JEN
Q3 202415 Jan 2026 - Revenue and profit fell in H1 2025, with guidance cut amid ongoing global uncertainties.JEN
Q2 20256 Jan 2026 - 2024 saw strong growth and margins, but 2025 outlook is cautious amid persistent uncertainties.JEN
Q4 20243 Dec 2025 - Revenue and EBITDA fell, but free cash flow and order intake improved amid market uncertainty.JEN
Q3 202512 Nov 2025 - Revenue and profit fell, but Biophotonics and cash flow improved; outlook remains cautious.JEN
Q1 20256 Jun 2025 - Record revenue and EBITDA in 2024, led by semiconductor growth, despite market headwinds.JEN
Q4 2024 TU5 Jun 2025